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Recurrent chromosomal translocations involving the mixed lineage leukemia gene (MLL) give rise to a highly aggressive acute leukemia associated with poor clinical outcome 1 . The preferential involvement of chromatin-associated factors in MLL rearrangement belies a dependency on transcription control 2 . Despite recent progress made in targeting chromatin regulators in cancer 3 , available therapies for this well-characterized disease remain inadequate, prompting the present effort to qualify new targets for therapeutic intervention. Using unbiased, emerging CRISPR-Cas9 technology to perform a genome-scale loss-of-function screen in MLL-AF4-positive acute leukemia, we identified ENL (eleven-nineteen leukemia) as an unrecognized dependency particularly indispensable for proliferation in vitro and in vivo. To explain the mechanistic role for ENL in leukemia pathogenesis and dynamic transcription control, we pursued a chemical genetic strategy utilizing targeted protein degradation. Acute ENL loss suppresses transcription initiation and elongation genome-wide, with pronounced effects at genes featuring disproportionate ENL load. Importantly, ENL-dependent leukemic growth was contingent upon an intact YEATS chromatin reader domain. These findings reveal a novel dependency in acute leukemia and a first mechanistic rational for disrupting the YEATS domain in disease.
Our group has longitudinally studied and targeted oncogenic transcription via disruption of chromatin-dependent signaling between oncogenic transcription factors and RNA polymerase (Pol) II. Previously, we collaboratively reported the function of acetyl-lysine binding factors, the BET bromodomain proteins (BRD2, BRD3, and BRD4), in enhancermediated transcription control of oncogenic MYC in hematologic malignancies 4, 5 , notably including MLL 6 . In MLL, aberrant chromatin structure is a hallmark feature that has been the focus of coordinated drug discovery efforts [7] [8] [9] [10] [11] [12] . Despite recent progress, these rearrangements still portend a poor prognosis requiring immediate intervention leveraging to high-risk protocols 1 , thus motivating our effort to illuminate new cancer-specific dependencies in MLL.
We undertook a genome-scale CRISPR/Cas9 knockout (GeCKO 13 ) screen in the wellstudied and MLL-AF4 rearranged human acute myeloid leukemia (AML) cell line, MV4;11 ( Table 1) . Changes in sgRNA abundance after 15 days of culturing was quantified by massively parallel DNA sequencing and analyzed by RIGER 14 , revealing several known MLL drivers (FLT3-ITD, HOXA9, and MEIS1) and essential genes (RPL9, GAPDH, ATP5B, and CDC23) as critical to proliferation 1, 15, 16 . Interestingly, sgRNAs targeting the YEATS (Yaf9, ENL, AF9, Taf14, Sas5) domain-containing ENL gene (also known as MLLT1) were among the most highly depleted, which given recent elucidation of the YEATS domain as a novel acyl-lysine reader module [17] [18] [19] [20] , prompted further investigation. ENL has been implicated in transcription control as a core component of the super elongation complex (SEC) [21] [22] [23] [24] [25] , which also includes the positive transcription elongation factor b (P-TEFb) heterodimer (CDK9 and CyclinT1). ENL has also been suggested to interact directly with DOT1L 21, 22, 23 , a critical and selective requirement in MLL-fusion leukemia 7, 9, 11, 12 , altogether supporting a rationale for ENL in MLL pathogenesis.
In order to validate ENL as a growth requirement, four additional sgRNAs were designed (Fig. 1b) and tested alongside the ENL-targeted sequence most highly depleted in the initial screen (sgENL_e1). Each was confirmed to mediate on-target Cas9 activity against ENL (Extended Data Fig. 1b) , inhibiting competitive growth of MV4;11 cells similarly to loss of FLT3 ( Fig. 1c and Extended Data Fig. 1c, d ), a bona fide target in the FLT3-ITD-positive cell line 15 . Of the 7 additional cell lines tested, each of which comparably express ENL, (Extended Data Fig. 1e ), the SEMK2 (MLL-AF4 ALL), OCI/AML-2 (MLL-AF6 AML), MOLM-13 (MLL-AF9 AML), NOMO-1 (MLL-AF9 AML), and SKM-1 (MLL wild-type AML) cell lines were sensitive to ENL loss, while only HL-60 (MLL wild-type AML) and JURKAT (T-ALL) were not (Fig. 1d, e and Extended Data Fig. 1f-j) . Additionally, an MV4;11 xenotransplantation model of disseminated leukemia in mice was sensitive to ENL loss, exhibiting marked reductions in disease progression and an overall survival benefit with CRISPR/Cas9 targeting ( Fig. 1f-h ). In contrast, competitive growth assays revealed that proliferation of lineage − , Sca1 + , c-Kit + (LSK) murine hematopoietic progenitors was minimally affected by Enl loss (Fig. 1i, Extended Data Fig. 2a, b) , qualifying ENL for further consideration as a leukemia target. Interestingly, but consistent with the initial GeCKO screen results, loss of the highly homologous YEATS-containing protein, AF9, had no observable anti-proliferative effects in MV4;11 or MOLM-13 cells (Extended Data Fig.  1l ), suggesting a specific, unique requirement for ENL function in acute leukemia.
Given the previous annotation of ENL as a transcriptional activator [21] [22] [23] [24] [25] , we hypothesized that ENL supports the pathogenesis of acute leukemia via maintenance of dysregulated gene expression. To test this, we employed a novel functional genetic strategy, building upon phthalimide conjugation of small molecules as an approach to achieve targeted protein degradation 26 . Using FKBP12 F36V as a protein tag for ENL, a hetero-bifunctional small molecule selectively targeting FKBP12 F36V and the E3 ubiquitin ligase, CRBN, induces degradation of the ENL chimera. Conveniently, the previously identified F36V mutation produces a "hole" in the protein surface that accommodates a complementary steric "bump" on the ligand 27 , thereby avoiding targeting of FKBP12 WT .
With a hemagglutinin (HA) epitope tag used for detection, ENL was expressed as amino and carboxy terminal FKBP12 F36V fusions in MV4;11-Cas9 cells and efficiently degraded at nanomolar concentrations by both dTAG-7 and dTAG-13 ( Fig. 2a and Extended Data Fig.  3a-d) , notably within 30 min or 1 hour, respectively ( Fig. 2b and Extended Data Fig. 3e ). This system proved amenable for use in multiple cellular systems (Extended Data Fig. 3f-h ) and durable over multiple days following a single treatment (Extended Data Fig. 3i, j) , particularly with dTAG-13 treatment, which led to its selection for further characterization. Upon selective inactivation of endogenous ENL and clonal expansion of lines bearing Nand C-terminal fusions (Extended Data Fig. 4a, b) , expression proteomics revealed exclusive loss of ENL with a single 3 hour dTAG-13 exposure (Fig. 2c) while FKBP12 WT is spared by this "bump-hole" strategy.
Administration of dTAG produced dose-responsive decreases in viability and potently suppressed proliferation in the absence of endogenous ENL ( Fig. 2d and Extended Data Fig.  4c-f) , with undetectable effects in wild-type MV4;11 cells (Extended Data Fig. 4g, h ). We focused subsequent analyses on the C-terminally tagged MV4;11 cell line (Cas9+, ENL-FKBP12 F36V -HA+, ENL −/− ) as it featured a doubling time (31.3 hr, least-squares nonlinear regression, R 2 = 0.956) closer to that of wild-type MV4;11 (25.8 hr, R 2 = 0.994) than did the N-terminally tagged line (35.0 hr, R 2 = 0.995). BrdU staining revealed that growth impairment downstream of pharmacologic ENL degradation can be attributed to rapid induction of G1 arrest and an accumulation of sub-G1 cells over 72 hours (Fig. 2e and Extended Data Fig. 4i ). Consistent with prior annotations of ENL as a transcriptional activator, we observed subtle loss of gene expression by cell-count normalized RNA-seq at 8 hours, followed by global downregulation of active transcripts at 24 and 96 hours (Fig. 2f) . We noted that several well-characterized leukemic drivers, including HOXA10, MYC, MYB, and MEIS1 were among the earliest and most severely downregulated transcripts, while the myeloid differentiation marker ITGAM (CD11b/MAC-1), was contrastingly upregulated (Fig. 2g) . Underlying global transcriptional defects at 24 hours was a concomitant decrease in RNA Pol II abundance at transcription start sites (TSS) and gene bodies of active genes (Fig. 2h, i) .
By chromatin immunoprecipitation and next-generation DNA sequencing (ChIP-seq), we found ENL-FKBP12 F36V genomic localization (using HA-directed antibody) in MV4;11 (Cas9+, ENL-FKBP12 F36V -HA, ENL −/− ) cells to be closely correlated with wild-type ENL in the parental MV4;11 cells (Extended Data Fig. 5a ), with each factor preferentially enriched at TSS ( By integrating these gene sets with kinetic gene expression profiling following dTAG-13 exposure, we uncovered preferential downregulation of asymmetrically enriched ENL target genes ( Fig. 3d and Extended Data Fig. 7a-c) , prompting further interrogation of classspecific RNA Pol II dynamics at ENL target genes. By ChIP-seq with cell-count normalization (ChIP-Rx), we uncovered preferential loss of RNA Pol II from the gene bodies of asymmetrically loaded targets, but with comparatively minimal effects at their TSS, reflecting a pause release defect at those genes ( Fig. 3e and Extended Data 7d, e). Given previous characterization of ENL as a member of the SEC, we reasoned these effects might be consequences of SEC recruitment to chromatin. To test this, we focused on the chromatin localization of AFF4 and CDK9, which are scaffolding and catalytic subunits of the SEC, respectively. Following a 6-hour treatment with dTAG-13, we uncovered an evident loss of AFF4 from promoters of asymmetrically, but not typically, loaded targets (Fig. 3f , h, i and Extended Data Fig. 7f, i) , which was accompanied also by a preferential loss of CDK9 from the promoters of those genes (Fig. 3g-i and Extended Data Fig. 7g, i) . This suggested that ENL may contribute to recruitment of the SEC to asymmetrically loaded target genes to promote productive elongation. To test this, we focused on the catalytic output of CDK9 activity (phosphorylation of Ser2 of the RNA Pol II C-terminal domain heptapeptide repeat) as a marker of elongating polymerase 31 . Following 24 hours of dTAG-13 treatment, we observe diminished pSer2-RNA Pol II enrichment specifically within gene bodies of ENL targets with asymmetric enrichment (Fig. 3h, i and Extended Data Fig. 7h, i) .
As ENL has been reported to bind directly to DOT1L 21, 22, 23 , we explored the functional relationship between these two factors. The rapid anti-proliferative response to ENL destabilization suggests a mechanism distinct from DOT1L function, as both genetic and chemical targeting of DOT1L is characterized by a delayed (7-10 day) effect on MLL growth and viability 7, 9 . Indeed, bulk levels of H3K79me2 were minimally changed by ENL degradation and only modest effects on locus-specific H3K79me2 were observed at asymmetric ENL target genes by ChIP-seq (Extended Data Fig. 8a-c) . As any changes to H3K79me2 occur several days after the first gene-expression changes occur following ENL degradation (96 hours versus 6 hours), we interpret these effects as secondary events attributable to the effect of ENL loss. To further dissect DOT1L-independent and DOT1L-dependent ENL phenotypes, we leveraged the rapid kinetics afforded by the dTAG/ENL system, finding that cell cycle and gene expression effects following ENL degradation were antecedent to those induced by DOT1L inhibition (Extended Data Fig. 8d, e) . Moreover, combination treatments for 96 hours revealed an additive effect on the suppression of MYC and HOXA9 transcription compared to either single agent treatment (Extended Data Fig. 8f ).
Also, while we were able to reproduce previous reports that DOT1L inhibition specifically downregulates MLL fusion target genes 7,9 , we did not uncover preferential suppression of published MLL-AF4 target genes following dTAG-13 treatment, and MLL-AF4 target genes exhibit minimal overlap with asymmetrically loaded ENL targets (Extended Data Fig. 8g-i) 10, 29 . Together, these data support that ENL degradation produces anti-leukemic effects on gene expression that occur, at least in part, through DOT1L-independent mechanisms. This agrees with the apparent ENL requirement in MLL WT acute leukemia (Extended Data Fig.  1h ), whereas DOT1L is selectively required in MLL-rearranged leukemia 7, 9 .
Given the evident addiction to ENL in acute leukemia cells, we employed saturating CRISPR-Cas9 mutagenesis to aid in the qualification of functionally relevant protein domains for drug discovery efforts 30 . We observed strong negative selection from sgRNAs targeting all annotated regions of ENL, with no regions emerging as a clear outlier (Fig. 4a) . Given the sensitivity of CRISPR-Cas9 directed at the YEATS domain, and our positive experience approaching acetyl-lysine recognition motifs with discovery chemistry, we explored whether ENL-dependent growth was contingent on YEATS domain function. Informed by published structure-function studies of the highly homologous AF9 17 , we engineered ENL mutations predicted to either minimally or severely affect acetyl-lysine recognition by featuring alanine replacements at Phe47 or Tyr78, respectively (Extended Data Fig. 9a ). As previously reported for AF9, we confirmed the ability of wild-type ENL to bind H3K9ac and H3K27ac, and that while this interaction was moderately affected by mutation of Phe47 to alanine, ENL Y78A exhibited a nearly complete inability to bind acetyllysine ( Fig. 4b and Extended Data Fig. 9b-d) . Despite equivalent expression, unaffected nuclear localization, and confirmed thermal stability in MV4;11-Cas9 cells (Extended Data Fig. 9e-h ), ENL F47A and ENL Y78A exhibited moderate and severe defects in the localization to chromatin, respectively (Fig. 4c-e) . Ultimately, these findings tracked with the ability of each construct to rescue loss of endogenous ENL (Fig. 4f) , providing genetic validation of the YEATS domain as a functional, emerging therapeutic target in leukemia.
In advance of identifying direct-acting inhibitors of ENL, we present data in support of a facile chemical biology platform to study dynamic cellular processes. We anticipate broad applicability of this technology beyond the scope of this study. We use the dTAG system to study the "fast biology" of transcription activation and elongation, capable of disentangling immediate versus secondary effects, complementing if not improving genetic perturbations (e.g. siRNA, CRISPR). Together, these studies provide support for a DOT1L-independent mechanism of leukemic maintenance, in which ENL recruitment of the SEC to promoters contributes to transactivation of as-yet undruggable oncogenes, such as MYC, MYB, and HOXA10. Importantly, whereas the role of ENL as a frequent fusion partner of MLL in leukemia has been known 1 , we report wild-type ENL, and specifically its YEATS domain, as an unrecognized cancer-specific dependency in acute leukemia. We and others may now pursue the discovery of chromatin-competitive antagonists of the ENL YEATS domain, with mechanistic guidance, as leukemia therapy.
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